Nektar Restructuring Ends Bempeg Ambitions, Cuts Staff By 70%
Executive Summary
Following termination of its immuno-oncology partnership with Bristol, Nektar is paring operations, closing its India site and focusing on mid-stage NKTR-358, partnered with Lilly, and NKTR-255.
You may also be interested in...
Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication
The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
Deal Watch: AI Specialist Biolojic Inks Diabetes Pact With Lilly, Autoimmune Tie-Up With Nektar
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.